Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 10/01/15

Dihydroorotate dehydrogenase inhibitors

Stowe et al. (86) confirmed COMPARE’s prediction that 2,2'-[3,3'-dimethoxy[1,1'-biphenyl]-(4,4'-diyl)diimino]bis(benzoic acid) (Redoxal) and 1-(p-bromophenyl)-2-methyl-1H-napth[2,3-d]imidazole-4,9-dione (BNID) were both dihydroorotate dehydrogenase (DHOD) inhibitors. Redoxal was identified by routine surveillance of screened output by using the standard agent database. Redoxal best correlated with the two DHOD inhibitors Brequinar and dichloroallyl lawsone. BNID, however, was identified by a retrospective COMPARE analysis against the entire synthetic compound database by using one of the known DHOD inhibitors as the seed.

Return to main page